Myeloproliferative Neoplasms Clinical Trial

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Summary

The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Male or female, aged 18 years and older
Chronic phase, Philadelphia Chromosome-positive chronic myeloid leukemia (CML)
Eastern Cooperative Oncology Group Performance Status score of 0-2

Key Exclusion Criteria:

Pleural Effusion
Uncontrolled cardiovascular disease
Significant bleeding disorder unrelated to CML
Prior treatment with interferon/imatinib/dasatinib/anti-CML systemic treatments except anagrelide/hydroxyurea

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 3

Estimated Enrollment:

547

Study ID:

NCT00481247

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 101 Locations for this study

See Locations Near You

Molecular Md
Portland Oregon, 97219, United States
Local Institution
Capital Federal Buenos Aires, 1280, Argentina
Local Institution
Capital Federal Buenos Aires, C1114, Argentina
Local Institution
Buenos Aires , 1021, Argentina
Local Institution
Waratah New South Wales, 2298, Australia
Local Institution
Brisbane Queensland, 4029, Australia
Local Institution
Greenslopes Queensland, 4120, Australia
Local Institution
Perth Western Australia, WA 60, Australia
Local Institution
Innsbruck , 6020, Austria
Local Institution
Wien , 1090, Austria
Local Institution
Brugge , 8000, Belgium
Local Institution
Bruxelles , 1200, Belgium
Local Institution
Curitiba Parana, 80060, Brazil
Local Institution
Campinas Sao Paulo, 13083, Brazil
Local Institution
Jau Sao Paulo, 17210, Brazil
Local Institution
Rio De Janeiro , 20230, Brazil
Local Institution
Sao Paulo , 01401, Brazil
Local Institution
Sao Paulo , 05403, Brazil
Local Institution
Santiago Metropolitana, , Chile
Local Institution
Beijing Beijing, 10004, China
Local Institution
Fuzhou Fujian, 35000, China
Local Institution
Shanghai Shanghai, 20002, China
Local Institution
Tianjin Tianjin, 30002, China
Local Institution
Colombia Bogota, , Colombia
Local Institution
Bogota , , Colombia
Local Institution
Brno , 625 0, Czech Republic
Local Institution
Hradec Kralove , 500 0, Czech Republic
Local Institution
Olomouc , 775 2, Czech Republic
Local Institution
Prague 2 , 128 2, Czech Republic
Local Institution
Aarhus , 8000, Denmark
Local Institution
Nantes Cedex 1, 44093, France
Local Institution
Brest Cedex 02 , 29609, France
Local Institution
Lille Cedex , 59037, France
Local Institution
Limoges , 87042, France
Local Institution
Montpellier Cedex , 34295, France
Local Institution
Paris Cedex 10 , 75475, France
Local Institution
Paris , 75015, France
Local Institution
Pierre Benite Cedex , 69495, France
Local Institution
Poitiers Cedex , 86021, France
Local Institution
Rennes , 35033, France
Local Institution
Strasbourg Cedex , 67091, France
Local Institution
Toulouse Cedex 09 , 31059, France
Local Institution
Vandoeuvre Les Nancy , 54511, France
Local Institution
Berlin , 13353, Germany
Local Institution
Rostock , 18055, Germany
Local Institution
Tuebingen , 72076, Germany
Local Institution
Ulm , 89081, Germany
Local Institution
Thessaloniki , 57010, Greece
Local Institution
Budapest , 1097, Hungary
Local Institution
Debrecen , 4012, Hungary
Local Institution
Vellore Tamilnadu, 63200, India
Local Institution
Ahmedabad , 38000, India
Local Institution
Cochin , 68230, India
Local Institution
Mumbai , 40001, India
Local Institution
Mumbai , 40001, India
Local Institution
Mumbai , 40001, India
Local Institution
Trivandrum , 69501, India
Local Institution
Bologna , 40138, Italy
Local Institution
Catania , 95124, Italy
Local Institution
Monza (mb) , 20900, Italy
Local Institution
Orbassano (to) , 10043, Italy
Local Institution
Pavia , 27100, Italy
Local Institution
Roma , 00144, Italy
Local Institution
Roma , 00161, Italy
Local Institution
Nagoya Aichi, 466-8, Japan
Local Institution
Kamogawa-shi Chiba, 29686, Japan
Local Institution
Fukuoka-shi Fukuoka, 814-0, Japan
Local Institution
Morioka-shi Iwate, 020-8, Japan
Local Institution
Kagoshima-shi Kagoshima, 890-0, Japan
Local Institution
Yokohama Kanagawa, 232-0, Japan
Local Institution
Kyoto-shi Kyoto, 60285, Japan
Local Institution
Sendai Miyagi, , Japan
Local Institution
Okayama-shi Okayama, 70085, Japan
Local Institution
Osaka-shi Osaka, 545-8, Japan
Local Institution
Bunkyo-ku Tokyo, 113-8, Japan
Local Institution
Shinagawa-ku Tokyo, 14186, Japan
Local Institution
Seoul , 137-0, Korea, Republic of
Local Institution
Seoul , 138-7, Korea, Republic of
Local Institution
Mexico D.f. Distrito Federal, 14000, Mexico
Local Institution
Mexico, D. F. Distrito Federal, 06726, Mexico
Local Institution
Mexico Distrito Federal, 02990, Mexico
Local Institution
Monterrey Nuevo Leon, 64460, Mexico
Local Institution
Culiacan Sinaloa, 80230, Mexico
Local Institution
Groningen , 9700 , Netherlands
Local Institution
Nijmegen , 6500 , Netherlands
Local Institution
Arequipa , , Peru
Local Institution
Lima , 11, Peru
Local Institution
Lima , 34, Peru
Local Institution
Chorzow , 41-50, Poland
Local Institution
Krakow , 31501, Poland
Local Institution
Lodz , 93-51, Poland
Local Institution
Poznan , 60869, Poland
Local Institution
Warsaw , 02776, Poland
Local Institution
Moscow , 12516, Russian Federation
Local Institution
Rostov-on-don , 34402, Russian Federation
Local Institution
St.petersburg , 19702, Russian Federation
Local Institution
Singapore , 16986, Singapore
Local Institution
A Coruna , 15706, Spain
Local Institution
Barcelona , 08003, Spain
Local Institution
Barcelona , 08036, Spain
Local Institution
Barcelona , 08907, Spain
Local Institution
Madrid , 28006, Spain
Local Institution
Madrid , 28046, Spain
Local Institution
Malaga , 29010, Spain
Local Institution
Oviedo , 33006, Spain
Local Institution
Salamanca , 37007, Spain
Local Institution
Valencia , 46009, Spain
Local Institution
Ankara , 06100, Turkey
Local Institution
Kayseri , 38039, Turkey

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 3

Estimated Enrollment:

547

Study ID:

NCT00481247

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider